Medium · Jan 2021
A Macromoltek blog post highlighting the team’s science focus and public content cadence, with broader interest in therapeutics and vaccine biology.
Public company, workplace, funding, and market signals
Austin-based biotech software company that uses AI and computational modeling to design, humanize, and optimize therapeutic antibodies for biotech and pharma partners.
Primary product
AI-driven antibody discovery and custom antibody design services/platform
Founded
2010
Headquarters
Austin, Texas, United States (2500 W. William Cannon Dr., Suite 204, Austin, TX 78745)
Team size
2-10
Industry
Biotechnology Research
Sub-industry
Computational drug discovery / antibody engineering
Offices
0 jobs at Macromoltek
Check back later for new openings
Business model
Stage
Seed
Total raised
$4.2M
Latest round
Loan · May 2020
Latest amount
$250K
Investors
Public reviews and company writing describe a small, collaborative, innovative startup environment with flexible/remote collaboration; reviewers also note a steep learning curve, startup-like pace, and weaker work-life balance/salary than they wanted.
Compensation
Public compensation signals are limited. Salary.com estimates average total compensation around $92.7k/year, while an Indeed reviewer said salary is 'currently lacking,' suggesting startup-scale pay.
Pricing
Custom B2B service engagements and partnership pricing; historical online workspace access was subscription-like.
Differentiators
Technology
Customers
Competitors
Estimated revenue
Public estimates conflict: about $210k/year (Growjo) to about $2.1M ARR (Latka)
Estimated monthly visits
828
Medium · Jan 2021
A Macromoltek blog post highlighting the team’s science focus and public content cadence, with broader interest in therapeutics and vaccine biology.
Medium · Oct 2020
Macromoltek discussed GPU-accelerated deep learning and NVIDIA/CUDA usage in antibody development, offering one of the clearest public windows into its technical stack and workflow.
Medium · Jun 2020
The company described how it kept antibody-design projects moving remotely during the pandemic, including a mix of engineering and lab work and more deliberate team coordination.
PR Newswire · Apr 2020
Macromoltek said it would apply its computational design platform to Cytovia Therapeutics' COVID-19 program, highlighting proprietary machine-learning/AI antibody design, remote delivery, and fast-track therapeutic candidate development.
PR Newswire · Apr 2020
Macromoltek announced a computational de novo antibody design offering for COVID-19, describing automated structural modeling and machine learning for rapid antibody design.